When researchers gave mice NLY01 on day 12 after CPZ induction, they observed more regrowth, or remyelination, in the treated mice compared to the control group
Capital Rx's Lauren Carroll, PharmD, BCACP (Manager, Clinical Programs), Angela Kalantarova, PharmD (Senior Manager, Clinical Programs), Brigitte Kinsey (Senior Manager, Clinical Analytics), Bonnie Hui-Callahan, PharmD, CDCES, (Senior Director, Clinical Programs), Jay Tran, PharmD, MHA(VP, Clinical Operations), and Sara Izadi, PharmD (Chief Clinical Officer) conducted a study seeking to measure the potential to reduce waste in for form of day supply overlap
Available: 0.25mg, 0.5mg, 1mg Metabolic Health Tirzepatide Dual GIP/GLP-1 receptor agonist representing the next generation of metabolic health therapeutics
Those with active malignancies or cancer history should still discuss peptide use with their healthcare providers